fingolimod hydrochloride has been researched along with Cirrhosis, Liver in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baweja, S; Bihari, C; Kumar, G; Kumar, J; Kumari, A; Maiwall, R; Mourya, AK; Negi, P; Rastogi, A; Reddy, GS; Sarin, SK; Sarohi, V; Sood, AK; Subudhi, PD; Thangariyal, S; Tomar, A; Tripathi, DM; Vashistha, C | 1 |
| Adams, DH; Frampton, J; Haldar, D; Henderson, NC; Houlihan, DD; Kalia, N; Kavanagh, D; King, A; Luu, N; Newsome, PN; Owen, A; Penny, J; Ramachandran, P; Reynolds, G; Sumption, H; Suresh, S; Than, NN | 1 |
| Kong, Y; Tang, N; Wang, H; Wang, S | 1 |
| Brunati, AM; Carraro, A; Cillo, U; D'Amico, F; Gringeri, E; Massimino, ML; Nalesso, G; Pagano, MA; Tibaldi, E; Toninello, A | 1 |
4 other study(ies) available for fingolimod hydrochloride and Cirrhosis, Liver
| Article | Year |
|---|---|
Hepatopulmonary syndrome is associated with low sphingosine-1-phosphate levels and can be ameliorated by the functional agonist fingolimod.
Topics: Animals; Fingolimod Hydrochloride; Hepatopulmonary Syndrome; Inflammation; Liver Cirrhosis; Mice; Niacinamide; Rats; Rats, Sprague-Dawley | 2023 |
Sphingosine-1-Phosphate Prevents Egress of Hematopoietic Stem Cells From Liver to Reduce Fibrosis.
Topics: Actins; Aldehyde-Lyases; Animals; Cell Line; Cell Movement; Chemical and Drug Induced Liver Injury, Chronic; Collagen Type I; Collagen Type I, alpha 1 Chain; Female; Fingolimod Hydrochloride; Gene Expression; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Immunosuppressive Agents; Liver; Liver Cirrhosis; Lymph; Lysophospholipids; Macrophages; Male; Membrane Proteins; Mice; Monocytes; Neutrophils; Phosphoric Monoester Hydrolases; Phosphotransferases (Alcohol Group Acceptor); Sphingosine | 2017 |
FTY720, a sphingosine-1 phosphate receptor modulator, improves liver fibrosis in a mouse model by impairing the motility of bone marrow-derived mesenchymal stem cells.
Topics: Animals; Bone Marrow Cells; Carbon Tetrachloride; Cell Movement; Disease Models, Animal; Fibrosis; Fingolimod Hydrochloride; Immunosuppressive Agents; Liver Cirrhosis; Mesenchymal Stem Cells; Mice; Mice, Inbred ICR; Mice, SCID; Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Wound Healing | 2014 |
Cross-talk between PDGF and S1P signalling elucidates the inhibitory effect and potential antifibrotic action of the immunomodulator FTY720 in activated HSC-cultures.
Topics: Animals; Cell Movement; Cell Proliferation; Cells, Cultured; Fingolimod Hydrochloride; Immunologic Factors; Liver; Liver Cirrhosis; Lysophospholipids; Male; Platelet-Derived Growth Factor; Propylene Glycols; Protein Transport; Rats; Rats, Wistar; Receptor Cross-Talk; Signal Transduction; Sphingosine | 2008 |